1,330,500 Shares in Editas Medicine, Inc. $EDIT Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP acquired a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,330,500 shares of the company’s stock, valued at approximately $4,310,820. Editas Medicine makes up about 0.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 27th largest position. Seven Fleet Capital Management LP owned 0.87% of Editas Medicine as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Editas Medicine in the 2nd quarter valued at approximately $34,312,000. ADAR1 Capital Management LLC acquired a new stake in shares of Editas Medicine during the 2nd quarter worth approximately $28,800,000. Renaissance Technologies LLC raised its holdings in Editas Medicine by 30.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock worth $9,811,000 after purchasing an additional 932,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Editas Medicine by 122.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after buying an additional 1,430,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Editas Medicine by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company’s stock worth $4,685,000 after acquiring an additional 244,574 shares during the period. Institutional investors and hedge funds own 71.90% of the company’s stock.

Insider Activity at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 15,380 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the transaction, the chief executive officer directly owned 248,313 shares in the company, valued at $670,445.10. This represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,503 shares of company stock valued at $57,910 in the last three months. Corporate insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Weiss Ratings raised shares of Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. LADENBURG THALM/SH SH assumed coverage on Editas Medicine in a research note on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target on the stock. Chardan Capital increased their target price on shares of Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Wednesday, May 27th. Finally, Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Editas Medicine Price Performance

Shares of EDIT stock traded down $0.14 during trading hours on Friday, reaching $3.16. 3,267,325 shares of the company traded hands, compared to its average volume of 2,114,405. Editas Medicine, Inc. has a 12-month low of $1.66 and a 12-month high of $4.54. The firm has a 50-day moving average price of $2.99 and a 200 day moving average price of $2.74. The company has a market cap of $485.31 million, a P/E ratio of -4.21 and a beta of 2.14.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.12. Editas Medicine had a negative return on equity of 196.63% and a negative net margin of 157.32%.The company had revenue of $11.89 million during the quarter, compared to analyst estimates of $2.85 million. Sell-side analysts predict that Editas Medicine, Inc. will post -0.85 EPS for the current year.

Editas Medicine News Roundup

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Zacks raised multiple EPS estimates. The research firm improved its forecasts for Q3 and Q4 2026, FY2026, every quarter of 2027, FY2027, and FY2028. The largest changes included FY2026 EPS improving to a loss of $0.90 from $1.25, FY2027 improving to a loss of $1.16 from $1.35, and FY2028 improving to a loss of $1.34 from $1.37. These revisions suggest analysts see Editas’ expected losses narrowing relative to prior projections. Editas Medicine stock information
• Neutral Sentiment: Editas remains unprofitable. Although the estimates improved, Zacks still projects losses across the forecast period, including a loss of $0.85 per share for the current fiscal year and a loss of $1.34 per share in FY2028. The revisions therefore represent reduced expected losses rather than a move toward near-term profitability.
• Neutral Sentiment: The revisions were concentrated in estimates, not business results. The reports did not cite new data regarding Editas’ gene-editing pipeline, clinical trials, partnerships, cash position, or regulatory milestones. Investors may therefore view the changes as modestly supportive but insufficient to materially change the company’s risk profile.

Editas Medicine Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.